Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Eslicarbazepine acetate as preventive therapy for patients with migraine: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Next Previous
Search
Trial Profile

Efficacy and safety of Eslicarbazepine acetate as preventive therapy for patients with migraine: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Therapeutic Use

    • Most Recent Events

    • 03 May 2014 Tolerability results from a pooled analysis of 5 trials in elderly patients who participated in non-epilepsy studies presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 29 Apr 2013 Status changed from recruiting to completed.
    • 02 Aug 2011 This trial is recruiting in Spain, but completed in Austria, Bulgaria, Czech Republic, Germany, Italy, Lithuania and Portugal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top